Skip to main content
ConductScienceScienceDex

Fanger, Gary

From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.

FY2023 NIH rank #1,009
Unclaimed recordClaim profile
  • Top 10% Funded
  • Early Career

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID unavailableSearch this ID in NIH RePORTER
ORCID iD
No ORCID iD on recordA researcher can add one by claiming this profile.
ScienceDex PI coverage
FY2018 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.

NIH Funding · FY2023

Linked Award Amount
$4.2M
Full award amounts, FY2023
Award Records
5
Records listing this PI
Award-Linked Rank
#1,009
By linked amount among FY2023 PIs
Earliest Year Loaded
2018
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Fanger, Gary. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2025 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2023 award records by amount

NIH award records listing Fanger, Gary as a PI. Multi-PI records show the full award amount for context.

  • 4R44DK133061-02R44Contact PI
    A Novel Immunological-Directed Live Biotherapy Product for Treating Ulcerative Colitis
    Rise Therapeutics, LLC
    $1M
    award amount
  • 5SB1DE030833-03SB1Contact PI
    A Novel Probiotic for the Treatment of Sjogren's Syndrome
    Rise Therapeutics, LLC
    $947.7K
    award amount
  • 5R44AI157031-03R44Contact PI
    A Novel Immunologically Enhanced Probiotic for Treating Rheumatoid Arthritis
    Rise Therapeutics, LLC
    $922.7K
    award amount
  • 5R44CA261509-03R44Contact PI
    A Novel Microbiome-Based Immune-Modulator that Potentiates Cancer Checkpoint Therapy
    Rise Therapeutics, LLC
    $828.1K
    award amount
  • 1R44AG084484-01R44Contact PI
    A Novel Immunological-Directed Biotherapy for Treating Rheumatoid Arthritis
    Rise Therapeutics, LLC
    $494.5K
    award amount

Award organization

Organizations that administered FY2023 awards listing Fanger, Gary as a PI.

FY2023 award administered by Rise Therapeutics, LLC (MD).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2018
    First NIH Award
    Rise Therapeutics, LLC
  2. 2018
    $500K Cumulative Funding
  3. 2019
    $1M Cumulative Funding
  4. 2019
    $2M Cumulative Funding
  5. 2019
    Entered Top 50% Nationally
    Ranked #6090
  6. 2021
    $5M Cumulative Funding
  7. 2021
    Entered Top 25% Nationally
    Ranked #964
  8. 2021
    Entered Top 10% Nationally
    Ranked #964
  9. 2021
    Entered Top 5% Nationally
    Ranked #964
  10. 2022
    $10M Cumulative Funding

Explore further

Find collaborators for Fanger, Gary

Search NIH-funded principal investigators by topic, department, or activity.

Open Find Collaborators →

Benchmark grant budgets

Compare median NIH grant budgets across departments, mechanisms, and years.

Open Grant Budget Benchmark →